|
|
||||||||
Ann Thorac Surg 2004;78:786-793
© 2004 The Society of Thoracic Surgeons
a Division of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
b Division of Cardiothoracic Surgery, University of Toronto, Toronto General Hospital, Toronto, Ontario, Canada
c Division of Cardiothoracic Surgery, Baylor College of Medicine, Houston, Texas, USA
d Department of Cardiothoracic Surgery, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA
Accepted for publication February 17, 2004.
* Address reprint requests to Dr Gleason, 3400 Spruce St, Silverstein 6, Division of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
thomas.gleason{at}uphs.upenn.edu
BACKGROUND: Several biological aortic root replacement techniques have distinct advantages over mechanical composite root replacement including better valvular hemodynamic characteristics and the lack of need for anticoagulation. Current biological root replacement options lack proven long-term durability or are limited by technical or practical concerns. We report the early results from a phase II multicenter clinical trial of the porcine St. Jude Toronto Bioprosthesis with BiLinx (Toronto root).
METHODS: 176 Toronto roots were implanted as total aortic root replacement from August 2001 through August 2003. Concomitant cardiac procedures including coronary artery bypass grafting (31%) and ascending aortic replacement (55%) were performed in 74%. Patients were followed clinically and were examined with an echocardiogram at discharge, 6 months, 12 months, and yearly thereafter. Root sizes implanted included 29 mm in 38%, 27 mm in 30%, 25 mm in 20%, 23 mm in 10%, and 21 mm in 2.2%.
RESULTS: There are 205 patient years of follow-up through October 2003. Operative mortality was 3.9% (none were valve related) and late mortality was 4%. Operative stroke rate was 1.1% and late stroke rate was 0.6%. Endocarditis developed in 1 patient. Freedom from aortic regurgitation is to date 100% at discharge, 6 months, and 1 year postimplant. Reoperation of the aortic valve/root was not required in any patient. Six-month mean transvalvular gradients for 2129 mm valves were 12.8, 8.8, 5.3, 4.9, and 4.7 mm Hg, respectively.
CONCLUSIONS: Aortic root replacement with the Toronto root is safe and provides superb transvalvular hemodynamics with freedom from anticoagulation. The Toronto root seems widely applicable for all types of aortic root pathology and these early data offer very encouraging results. Long-term follow-up is required.
This article has been cited by other articles:
![]() |
W. Y. Szeto, J. E. Bavaria, F. W. Bowen, A. Geirsson, K. Cornelius, W. C. Hargrove, and A. Pochettino Reoperative Aortic Root Replacement in Patients With Previous Aortic Surgery Ann. Thorac. Surg., November 1, 2007; 84(5): 1592 - 1599. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lima, G. C. Hughes, A. Lemaire, J. Jaggers, D. D. Glower, and W. G. Wolfe Short-Term and Intermediate-Term Outcomes of Aortic Root Replacement with St. Jude Mechanical Conduits and Aortic Allografts Ann. Thorac. Surg., August 1, 2006; 82(2): 579 - 585. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |